Charles K. Gayer's most recent trade in Biocryst Pharmaceuticals Inc. was a trade of 50,000 Emp. Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Dec. 19, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Biocryst Pharma Inc | Charles K. Gayer | President and CCO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Dec 2025 | 50,000 | 0 | - | - | Emp. Stock Option (Right to Buy) | |
| Biocryst Pharma Inc | Charles K. Gayer | President and CCO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.51 per share. | 19 Dec 2025 | 50,000 | 952,583 (0%) | 0% | 5.5 | 275,500 | Common Stock |
| Biocryst Pharma Inc | Charles K. Gayer | President and CCO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.22 per share. | 19 Dec 2025 | 14,142 | 892,492 (0%) | 0% | 3.2 | 45,537 | Common Stock |
| Biocryst Pharma Inc | Charles K. Gayer | President and CCO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Dec 2025 | 14,142 | 0 | - | - | Emp. Stock Option (Right to Buy) | |
| Biocryst Pharma Inc | Charles K. Gayer | President and CCO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.41 per share. | 19 Dec 2025 | 11,477 | 878,350 (0%) | 0% | 7.4 | 85,045 | Common Stock |
| Biocryst Pharma Inc | Charles K. Gayer | President and CCO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.04 per share. | 19 Dec 2025 | 10,091 | 902,583 (0%) | 0% | 5.0 | 50,859 | Common Stock |
| Biocryst Pharma Inc | Charles K. Gayer | President and CCO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Dec 2025 | 10,091 | 17,409 | - | - | Emp. Stock Option (Right to Buy) | |
| Biocryst Pharma Inc | Charles K. Gayer | President and CCO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Dec 2025 | 986,950 | 986,950 | - | - | Emp. Stock Option (Right to Buy) | |
| Biocryst Pharma Inc | Charles K. Gayer | President and CCO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Dec 2025 | 471,000 | 889,827 (0%) | 0% | 0 | Common Stock | |
| Biocryst Pharma Inc | Charles K. Gayer | President and CCO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.57 per share. | 12 Dec 2025 | 8,181 | 418,827 (0%) | 0% | 7.6 | 61,930 | Common Stock |
| Biocryst Pharma Inc | K. Gayer Charles | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Dec 2024 | 260,950 | 260,950 | - | - | Emp. Stock Option (Right to Buy) | |
| Biocryst Pharma Inc | Gayer K. Charles | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Dec 2024 | 125,950 | 426,007 (0%) | 0% | 0 | Common Stock | |
| Biocryst Pharma Inc | Charles Gayer K. | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.39 per share. | 19 Dec 2024 | 2,461 | 423,546 (0%) | 0% | 7.4 | 18,187 | Common Stock |
| Biocryst Pharma Inc | Charles K. Gayer | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.53 per share. | 14 Dec 2024 | 8,251 | 300,057 (0%) | 0% | 7.5 | 62,130 | Common Stock |
| Biocryst Pharma Inc | Charles K. Gayer | Chief Commercial Officer | Purchase of securities on an exchange or from another person at price $ 5.47 per share. | 13 May 2024 | 30,000 | 307,533 (0%) | 0% | 5.5 | 164,100 | Common Stock |
| Biocryst Pharma Inc | Gayer Charles K. | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.05 per share. | 19 Dec 2023 | 2,482 | 274,533 (0%) | 0% | 6.0 | 15,016 | Common Stock |
| Biocryst Pharma Inc | K. Gayer Charles | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Dec 2023 | 158,500 | 158,500 | - | - | Emp. Stock Option (Right to Buy) | |
| Biocryst Pharma Inc | Gayer K. Charles | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Dec 2023 | 34,000 | 282,855 (0%) | 0% | 0 | Common Stock | |
| Biocryst Pharma Inc | Gayer K. Charles | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.43 per share. | 14 Dec 2023 | 5,840 | 277,015 (0%) | 0% | 6.4 | 37,551 | Common Stock |
| Biocryst Pharma Inc | Charles K. Gayer | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Dec 2022 | 158,500 | 158,500 | - | - | Emp. Stock Option (Right to Buy) | |
| Biocryst Pharma Inc | Charles K. Gayer | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Dec 2022 | 34,000 | 245,610 (0%) | 0% | 0 | Common Stock | |
| Biocryst Pharma Inc | Charles K. Gayer | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 10.90 per share. | 15 Dec 2022 | 6,100 | 211,610 (0%) | 0% | 10.9 | 66,490 | Common Stock |
| Biocryst Pharma Inc | Charles K. Gayer | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Dec 2021 | 164,000 | 164,000 | - | - | Emp. Stock Option (Right to Buy) | |
| Biocryst Pharma Inc | Charles K. Gayer | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Dec 2021 | 125,000 | 261,556 (0%) | 0% | 0 | Common Stock |